CCCC
NASDAQ · Biotechnology
C4 Therapeutics Inc
$3.12
+0.14 (+4.53%)
Open$3.02
Previous Close$2.98
Day High$3.16
Day Low$2.98
52W High$5.17
52W Low$1.69
Volume—
Avg Volume2.08M
Market Cap366.61M
P/E Ratio—
EPS$-1.00
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+1,159.7% upside
Current
$3.12
$3.12
Target
$39.24
$39.24
$29.92
$39.24 avg
$50.68
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 51.61M | 49.18M | 17.10M |
| Net Income | -150,764,426 | -129,288,216 | 3.03M |
| Profit Margin | -292.1% | -277.5% | 17.7% |
| EBITDA | -162,643,701 | -147,223,931 | 5.37M |
| Free Cash Flow | — | — | 3.54M |
| Rev Growth | +5.0% | +5.0% | +6.2% |
| Debt/Equity | — | — | 1.00 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |